Investigation of Association Between Borderline Pancreatic Head Cancer and Glucose Uptake by Using Positron-Emission Tomographic Studies

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2017 Oct 17

PMID 29036034

Authors

Ying Zhang

Lei Qin

Changming Zhang

Affiliations

Soon will be listed here.

Abstract

BACKGROUND In the background of the well-known importance of positron-emission tomographic studies (PET) in the prediction of pancreatic oncologic problems, we designed and performed this investigation to study the link between borderline pancreatic head cancer and glucose uptake by using PET. MATERIAL AND METHODS We retrospectively investigated patients during the period of almost 4 years (May 2013 to December 2016). Patients underwent potentially curative resection for borderline exocrine pancreatic head adenocarcinoma without undergoing neoadjuvant therapy. We divided our PET protocol into 2 sets of methods as per renal calyces: 1) U-RC type in which renal calyx (RC) has relatively higher value than that of 18F-fluoro-2-deoxyglucose (18F-FDG) uptake and 2) S-RC type in which renal calyx has similar value than that of 18F-FDG uptake. RESULTS A total of 67 patients were enrolled after reclassification on the basis of majority-agreement. Among these patients, U-RC type was found in 22 patients (32.8%) while S-RC type was found in 45 patients (67.2%). Significant statistical differences were observed for each of the 2 types of pancreatic head cancer (U-RC type and S-RC type) in terms of adjusted cancer antigen 19-9 (CA 19-9), size of the tumor, tumor volume (TV2.8), maximum standard uptake value (SUV↑), and lesion glycolysis (LG). A significantly longer disease-free survival time was shown by U-RC type (n=18) pancreatic cancer in comparison to S-RC type (n=42) (25.3 vs. 11.2 months). Additionally, U-RC type (n=4) had higher disease-free survival than did aS-RC type (n=3) (29.4 vs. 12.5 months). CONCLUSIONS Our PET protocol appears to be an indicator for estimation of recurrence of pancreatic head cancer and is as an indispensable asset to oncologists.

References

Schellenberg D, Quon A, Minn A, Graves E, Kunz P, Ford J . 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 77(5):1420-5. DOI: 10.1016/j.ijrobp.2009.06.049. View

Jones T, Price P . Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncol. 2012; 13(3):e116-25. DOI: 10.1016/S1470-2045(11)70183-8. View

Kim M, Lee M, Choi J, Park Y . Imaging features of small hepatocellular carcinomas with microvascular invasion on gadoxetic acid-enhanced MR imaging. Eur J Radiol. 2011; 81(10):2507-12. DOI: 10.1016/j.ejrad.2011.11.014. View

Liao S, Penney B, Wroblewski K, Zhang H, Simon C, Kampalath R . Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011; 39(1):27-38. DOI: 10.1007/s00259-011-1934-6. View

Kauhanen S, Komar G, Seppanen M, Dean K, Minn H, Kajander S . A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009; 250(6):957-63. DOI: 10.1097/SLA.0b013e3181b2fafa. View

Monjazeb A, Riedlinger G, Aklilu M, Geisinger K, Mishra G, Isom S . Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol. 2010; 28(31):4714-21. PMC: 3020701. DOI: 10.1200/JCO.2010.30.7702. View

Fukukura Y, Takumi K, Kamimura K, Shindo T, Kumagae Y, Tateyama A . Pancreatic adenocarcinoma: variability of diffusion-weighted MR imaging findings. Radiology. 2012; 263(3):732-40. DOI: 10.1148/radiol.12111222. View

Im H, Oo S, Jung W, Jang J, Kim S, Cheon G . Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer. Medicine (Baltimore). 2016; 95(19):e3686. PMC: 4902549. DOI: 10.1097/MD.0000000000003686. View

Jacene H, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O . Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009; 50(11):1760-9. DOI: 10.2967/jnumed.109.063321. View

10.

Kubota K, Furumoto S, Iwata R, Fukuda H, Kawamura K, Ishiwata K . Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med. 2006; 20(8):527-33. DOI: 10.1007/BF03026816. View

11.

Kim M, Lee K, Lee K, Lee J, Ku B, Oh C . The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. Pancreas. 2012; 41(6):897-903. DOI: 10.1097/MPA.0b013e318252f4f5. View

12.

Chirindel A, Alluri K, Chaudhry M, Wahl R, Pawlik T, Herman J . Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. AJR Am J Roentgenol. 2015; 204(5):1093-9. DOI: 10.2214/AJR.14.13156. View

13.

Toriihara A, Kitazume Y, Nishida H, Kubota K, Nakadate M, Tateishi U . Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls. Am J Nucl Med Mol Imaging. 2015; 5(2):204-11. PMC: 4396005. View

14.

Schaarschmidt B, Grueneisen J, Heusch P, Gomez B, Umutlu L, Ruhlmann V . Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?. Nucl Med Commun. 2015; 36(6):588-95. DOI: 10.1097/MNM.0000000000000298. View

15.

Kawada N, Uehara H, Hosoki T, Takami M, Shiroeda H, Arisawa T . Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors. Pancreas. 2015; 44(4):655-9. DOI: 10.1097/MPA.0000000000000313. View

16.

Adams M, Turkington T, Wilson J, Wong T . A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010; 195(2):310-20. DOI: 10.2214/AJR.10.4923. View

17.

Ahn S, Park M, Lee J, Kang W . Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer. Ann Nucl Med. 2014; 28(5):430-5. DOI: 10.1007/s12149-014-0833-x. View

18.

Smyth E, Shah M . Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol. 2011; 17(46):5059-74. PMC: 3235589. DOI: 10.3748/wjg.v17.i46.5059. View

19.

Xu H, Chen T, Wang W, Wu C, Liu C, Long J . Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 2014; 41(6):1093-102. DOI: 10.1007/s00259-014-2688-8. View

20.

Lee J, Kang C, Choi H, Lee W, Song S, Lee J . Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. J Nucl Med. 2014; 55(6):898-904. DOI: 10.2967/jnumed.113.131847. View